Assign modules on offcanvas module position to make them visible in the sidebar.

ALBUCID-DF

eye drops 20%, 30%, 10 ml

Dispensing conditions: NO PRESCRIPTION 

Фарм.группа: Medications for eye diseases

THERAPEUTIC INDICATIONS:

  • purulent corneal ulcers;

  • infectious conjunctivitis;

  • blepharitis;

  • prevention and treatment of gonorrheal eye disease in newborns and adults;

  • prevention of neonatal blenorrhea;

  • prevention of purulent complications after eye injuries and surgeries.

dwldDownload instructions for use

Composition

1 ml of the product contains:

  • active substance sodium sulfacetamide - 0.2 g0.3 g;              
  • excipients: sodium thiosulfate, hydrochloric acid solution 1 M, water for injection.

Pharmaceutical form

Eye drops 20%, 30% 5 ml, 10 ml, 15 ml.

Pharmacotherapeutic group

Medications for eye diseases. Antimicrobials. Sulfonamides. Sulfacetamide.

ATC code S01AВ04

Indications

  • purulent corneal ulcers;
  • infectious conjunctivitis;
  • blepharitis;
  • prevention and treatment of gonorrheal eye disease in newborns and adults;
  • prevention of neonatal blenorrhea;
  • prevention of purulent complications after eye injuries and surgeries.

Contraindications

hypersensitivity to sodium sulfacetamide and excipients of the product.

Posology and method of administration

For the treatment and prevention of infectious eye diseases:

Adults: Instill Albuzid-DF® 30% solution in eyes 1-2 drops 2-3 times a day, once the acute pyo-inflammatory process has disappeared, put 1-2 drops in your eyes 3 times a day

For children over 1 year of age: Albuzid-DF® 20% solution is used 1-2 drops 4-5 times a day, after acute pyo-inflammatory process disappears - 1-2 drops 3 times a day

The course of treatment is 5-7 days.

To prevent newborns' blennorrhea, instill 2 drops of a 20% solution of the product into each eye immediately after birth and then 2 drops every 2 hours thereafter.

Adverse reactions

  • redness, pain, lacrimation;
  • itching, swelling of the eyelids;
  • a brief burning sensation;
  • local allergic reactions.

Overdose

There is no evidence of product overdose.

Use during pregnancy or breastfeeding

Use of the product during pregnancy and lactation is possible only if the expected benefits to the mother exceed the risk to the fetus and the baby.

Pediatric population

Allowed for newborns.

Special warnings

Make sure that the tip of the dropper bottle does not come into contact with other objects or surfaces when instilling. Close the dropper bottle tightly with the cap after instillation!
In case of tissue irritation, less concentrated solutions are prescribed.
Patients with hypersensitivity to furosemide, thiazide diuretics (hydrochlorthiazide), sulfonylurea derivatives (glibenclamide), carbohydrate inhibitors (diacarb) may have hypersensitivity to Albuzid-DF®.
Effects on ability to drive and use machines
Use the product with caution when driving a vehicle or using potentially dangerous machinery, taking into account the side effects.

Presentation and package

5 ml, 10 ml or 15 ml of the product in plastic dropper bottles, sealed with tamper-proof caps, or in plastic dropper bottles, sealed with caps. One bottle is with instruction for use in the state and Russian language are placed in a carton pack.

Storage conditions

In a place protected from light, at a temperature of 150С to 250С.

Keep out of the reach of children.

Shelf life

2 years

After opening the bottle, the period of using the product is 10 days.

Manufacturer

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan, tel.: (727) 253-03-88.

Marketing authorization holder

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan.

Name, address, contact information of the organization accepting claims (proposals) against quality of products from consumers in the territory of the Republic of Kazakhstan, which is responsible for post-authorization safety surveillance of the medicine:

"DOSFARM" LLP, 3 Chaplygin street, Almaty city, 050034, Kazakhstan,

Tel./Fax: (727) 253-07-07, 253-03-88, e-mail: Адрес электронной почты защищен от спам-ботов. Для просмотра адреса в вашем браузере должен быть включен Javascript.

Задать вопрос по этому препарату